A comparison of the reactivating and therapeutic efficacy of two novel bispyridinium oximes (K305, K307) with the oxime K203 and trimedoxime in tabun-poisoned rats and mice

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F60162694%3AG44__%2F17%3A43875733" target="_blank" >RIV/60162694:G44__/17:43875733 - isvavai.cz</a>

Výsledek na webu

<a href="http://www.sciencedirect.com/science/article/pii/S1214021X16301041" target="_blank" >http://www.sciencedirect.com/science/article/pii/S1214021X16301041</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.jab.2016.09.008" target="_blank" >10.1016/j.jab.2016.09.008</a>

Jazyk výsledku

angličtina

Název v původním jazyce

A comparison of the reactivating and therapeutic efficacy of two novel bispyridinium oximes (K305, K307) with the oxime K203 and trimedoxime in tabun-poisoned rats and mice

Popis výsledku v původním jazyce

The reactivating and therapeutic efficacy of two newly developed oximes (K305, K307) was compared with the oxime K203 and trimedoxime using in vivo methods The study determining percentage of reactivation of tabun-inhibited acetylcholinesterase in the peripheral as well as central nervous system (diaphragm, brain) in tabun-poisoned rats showed that the reactivating efficacy of both newly developed oximes is lower compared to the reactivating efficacy of the oxime K203 and trimedoxime. The therapeutic efficacy of all oximes studied roughly corresponds to their reactivating efficacy. While the ability of the oxime K305 to reduce acute toxicity of tabun in mice is approaching to the therapeutic efficacy of trimedoxime, the ability of another novel bispyridinium oxime K307 to reduce acute toxicity of tabun is significantly lower compared to trimedoxime and the oxime K203. Thus, the reactivating and therapeutic efficacy of both examined newly developed oximes does not prevail the effectiveness of the oxime K203 and trimedoxime and, therefore, they are not suitable for their replacement of commonly used oximes for the treatment of acute tabun poisoning. (C) 2016 Published by Elsevier Sp. z o.o. on behalf of Faculty of Health and Social Sciences, University of South Bohemia in Ceske Budejovice.

Název v anglickém jazyce

A comparison of the reactivating and therapeutic efficacy of two novel bispyridinium oximes (K305, K307) with the oxime K203 and trimedoxime in tabun-poisoned rats and mice

Popis výsledku anglicky

The reactivating and therapeutic efficacy of two newly developed oximes (K305, K307) was compared with the oxime K203 and trimedoxime using in vivo methods The study determining percentage of reactivation of tabun-inhibited acetylcholinesterase in the peripheral as well as central nervous system (diaphragm, brain) in tabun-poisoned rats showed that the reactivating efficacy of both newly developed oximes is lower compared to the reactivating efficacy of the oxime K203 and trimedoxime. The therapeutic efficacy of all oximes studied roughly corresponds to their reactivating efficacy. While the ability of the oxime K305 to reduce acute toxicity of tabun in mice is approaching to the therapeutic efficacy of trimedoxime, the ability of another novel bispyridinium oxime K307 to reduce acute toxicity of tabun is significantly lower compared to trimedoxime and the oxime K203. Thus, the reactivating and therapeutic efficacy of both examined newly developed oximes does not prevail the effectiveness of the oxime K203 and trimedoxime and, therefore, they are not suitable for their replacement of commonly used oximes for the treatment of acute tabun poisoning. (C) 2016 Published by Elsevier Sp. z o.o. on behalf of Faculty of Health and Social Sciences, University of South Bohemia in Ceske Budejovice.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30108 - Toxicology

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2017

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Journal of Applied Biomedicine

ISSN

1214-021X

e-ISSN

—

Svazek periodika

15

Číslo periodika v rámci svazku

1

Stát vydavatele periodika

CZ - Česká republika

Počet stran výsledku

5

Strana od-do

49-53

Kód UT WoS článku

000396404200007

EID výsledku v databázi Scopus

2-s2.0-84992313157